Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Whitehawk Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
WHWK
Nasdaq
2836
ir.whitehawktx.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Whitehawk Therapeutics, Inc.
Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026
- May 30th, 2026 12:30 pm
Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference
- May 28th, 2026 2:05 pm
Acuta Capital Sells 56% of Ocular Therapeutix Shares in Q1
- May 26th, 2026 4:26 pm
WHWK Stock Edges Up After Hours: Firm Boosts Pipeline Of Cancer Drugs On The Heels Of Capital Raise
- May 21st, 2026 6:38 pm
Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload
- May 21st, 2026 3:05 pm
Whitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit
- May 20th, 2026 6:00 am
Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy
- May 16th, 2026 9:01 am
Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum
- May 15th, 2026 6:00 am
May 2026's Promising Penny Stocks
- May 14th, 2026 6:04 am
12 Health Care Stocks Moving In Wednesday's Intraday Session
- May 13th, 2026 11:06 am
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- May 13th, 2026 6:06 am
Whitehawk Therapeutics Announces $87.5M Private Placement Equity Financing
- May 13th, 2026 6:00 am
Whitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
- May 7th, 2026 6:00 am
Whitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AACR 2026
- Apr 19th, 2026 4:00 pm
Whitehawk Therapeutics to Participate in Jones Trading Post-AACR Fireside Chat Series
- Apr 16th, 2026 2:05 pm
Discovering Whitehawk Therapeutics Among 3 Promising Penny Stocks
- Apr 15th, 2026 6:05 am
Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as a Highly Expressed, Clinically Relevant Target for Gynecologic Cancers at SGO 2026
- Apr 10th, 2026 5:00 am
Whitehawk Therapeutics to Highlight its Next-Generation ADC Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026
- Mar 17th, 2026 2:30 pm
Whitehawk Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights
- Mar 12th, 2026 6:00 am
Aadi Bioscience Conference: Whitehawk Unveils 3-Program ADC Pipeline, Targets First Data in 2027
- Mar 10th, 2026 11:55 am
Scroll